Aspen Neuroscience has announced that its investigational autologous cell therapy, previously known as ANPD001, will now be referred to as Sasineprocel, following approval from the World Health Organization and the American Medical Association. This innovative therapy utilizes dopaminergic neuron precursor cells derived from a patient’s own induced pluripotent stem cells, aiming to restore dopamine-producing neurons lost in Parkinson’s disease without the need for immunosuppressive drugs.

The adoption of the nonproprietary name marks a significant step in the regulatory and clinical journey of Sasineprocel, which is currently under evaluation in the Phase 1/2a ASPIRO clinical study. This trial focuses on individuals with moderate to advanced Parkinson’s disease and continues to assess both safety and potential efficacy. The therapy has also received Fast Track designation from the FDA, underscoring its therapeutic promise.

For professionals in the longevity and healthspan research fields, the progress of Sasineprocel represents an important advancement in personalized regenerative therapies for neurodegenerative diseases. I encourage you to read the full article to delve deeper into Aspen’s work and the implications for future treatments.

Source: longevity.technology